Eton Pharmaceuticals names new chief operating officer
Eton Pharmaceuticals, Inc. appointed Danka Radosavljevic, age 42, as Chief Operating Officer on July 31, 2026.
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. appointed Danka Radosavljevic, age 42, as Chief Operating Officer on July 31, 2026. She has been with the company since 2017 and most recently served as Executive Vice President, Operations overseeing quality, product development, regulatory, supply chain and information systems.
Her compensation package includes an annual base salary of $520,800 and an annual discretionary incentive bonus with a target of 50% of base salary, contingent on corporate and/or individual performance targets to be approved by the Board of Directors.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
COO appointment date: July 31, 2026
COO age: 42 years
Annual base salary: $520,800
+2 more
5 metrics
COO appointment date
July 31, 2026
Date Danka Radosavljevic was appointed Chief Operating Officer
COO age
42 years
Age of Danka Radosavljevic at time of appointment as COO
Annual base salary
$520,800
Base salary for Danka Radosavljevic as Chief Operating Officer
Annual bonus target
50% of base salary
Target discretionary incentive bonus as COO, subject to performance
Company tenure start year
2017
Year Danka Radosavljevic joined Eton Pharmaceuticals
Key Terms
Chief Operating Officer, annual discretionary incentive bonus, Executive Vice President, Operations, emerging growth company
4 terms
Chief Operating Officer financial
"appointed Danka Radosavljevic (age 42) as Chief Operating Officer"
A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.
annual discretionary incentive bonus financial
"an annual discretionary incentive bonus at a total annual target amount of 50%"
Executive Vice President, Operations financial
"previously held the position of Executive Vice President, Operations at the Company"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive change did Eton Pharmaceuticals (ETON) announce on July 31, 2026?
Eton Pharmaceuticals appointed Danka Radosavljevic as Chief Operating Officer on July 31, 2026. She previously served as Executive Vice President, Operations, overseeing quality, product development, regulatory, supply chain and information systems for more than the past five years.
What is the new COO’s compensation package at Eton Pharmaceuticals (ETON)?
The new COO receives an annual base salary of $520,800 plus an annual discretionary incentive bonus targeted at 50% of base salary. The bonus depends on corporate and/or individual performance targets set and approved by Eton Pharmaceuticals’ Board of Directors.
What role did Danka Radosavljevic hold at Eton Pharmaceuticals (ETON) before becoming COO?
Before becoming COO, Danka Radosavljevic was Executive Vice President, Operations at Eton Pharmaceuticals. In that role she oversaw quality, product development, regulatory, supply chain and information systems and has been with the company since 2017.
How long has Eton Pharmaceuticals (ETON)’s new COO been with the company?
Danka Radosavljevic has been with Eton Pharmaceuticals since 2017. Over more than five years, she has led operational areas including quality, product development, regulatory, supply chain and information systems before her appointment as Chief Operating Officer on July 31, 2026.
Who signed the Eton Pharmaceuticals (ETON) report regarding the COO appointment?
The report was signed by Judith M. Matthews, Chief Financial Officer and Secretary, identified as the company’s principal financial officer. Her signature indicates the company’s authorization of the disclosed executive appointment and related compensation details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
